<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01016548</url>
  </required_header>
  <id_info>
    <org_study_id>09-0780-C</org_study_id>
    <secondary_id>INVC-2009-0241</secondary_id>
    <nct_id>NCT01016548</nct_id>
  </id_info>
  <brief_title>Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on Chemotherapy</brief_title>
  <official_title>Evaluation of Pandemic H1N1(2009) Influenza Vaccine in Adults With Lymphoid Malignancies on Active Systemic Treatment or Post Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Princess Margaret Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether adults with hematologic malignancies on
      active systemic therapy or shortly after bone marrow transplantation need one or two doses of
      adjuvanted vaccine to achieve best possible rates of protection. An additional research
      question is whether baseline biomarkers of the cellular and humoral immune systems are
      associated with an antibody response to vaccination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The novel influenza H1N1 virus responsible for a world-wide pandemic throughout 2009
      (H1N1(2009)) is expected to cause a second wave of infection during the 2009/10 winter
      season. Vaccines against H1N1(2009) will be available in early November, 2009. Adults with
      hematologic disorders are at high risk of influenza-related complications, including death.
      Given that the vaccination dosing for the pandemic vaccine has been developed on healthy
      individuals, it is unknown whether this subgroup of patients will respond similarly. We will
      evaluate the safety and efficacy of the pandemic vaccine in patients with lymphoid
      malignancies receiving active systemic treatment, or who have recently undergone stem cell
      transplantation. Patients will be randomized to one or two doses of the approved adjuvanted
      vaccine; immune responses will be measured to identify the optimal regimen. Also, we will
      look for an association between biomarkers of the immune system and a response to the
      vaccine; this will be done by measuring baseline CD3, 4, 8, 19, and 56 cells by flow
      cytometry.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion rates.</measure>
    <time_frame>Day 0, 21, 42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events to vaccination.</measure>
    <time_frame>Day 7, 21, 28.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Influenza A Virus, H1N1 Subtype</condition>
  <arm_group>
    <arm_group_label>Two doses of vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Second dose is given 21 days after the initial dose. The same dose and route of administration are used.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>One dose of vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Given at baseline only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AS03-adjuvanted H1N1 pandemic influenza vaccine</intervention_name>
    <description>One dose constitutes 0.5mL of suspended vaccine via the intramuscular route.</description>
    <arm_group_label>Two doses of vaccine</arm_group_label>
    <arm_group_label>One dose of vaccine</arm_group_label>
    <other_name>Arepanrix(R)</other_name>
    <other_name>ATC Code J07BB02</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, ages 20-65

          -  Diagnosis of lymphoproliferative disorder

          -  One of the following types of systemic treatment: active chemo/immunotherapy at
             enrollment or completed within the last 3 months, OR auto/allo stem cell transplant
             recipient within the past 12 months

          -  Able to provide consent and comply with trial requirements

        Exclusion Criteria:

          -  Systemic hypersensitivity to hen's eggs, thimerosal, gentamicin

          -  History of life-threatening reaction to prior influenza vaccination

          -  Thrombocytopenia or bleeding disorder contraindicating IM injection

          -  Pregnancy

          -  Laboratory-confirmed infection with H1N1(2009)

          -  IVIG infusion within the last three months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Kuruvilla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.hc-sc.gc.ca/dhp-mps/prodpharma/legislation/interimorders-arretesurgence/prodinfo-vaccin-eng.php</url>
    <description>Arepanrix(R) Product Information Leaflet</description>
  </link>
  <reference>
    <citation>Carter NJ, Plosker GL. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus. BioDrugs. 2008;22(5):279-92. Review.</citation>
    <PMID>18778110</PMID>
  </reference>
  <reference>
    <citation>Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D, Basser RL. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med. 2009 Dec 17;361(25):2405-13. doi: 10.1056/NEJMoa0907413. Epub 2009 Sep 10.</citation>
    <PMID>19745216</PMID>
  </reference>
  <reference>
    <citation>Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med. 2009 Dec 17;361(25):2424-35. doi: 10.1056/NEJMoa0907650. Epub 2009 Sep 10.</citation>
    <PMID>19745215</PMID>
  </reference>
  <reference>
    <citation>Zhu FC, Wang H, Fang HH, Yang JG, Lin XJ, Liang XF, Zhang XF, Pan HX, Meng FY, Hu YM, Liu WD, Li CG, Li W, Zhang X, Hu JM, Peng WB, Yang BP, Xi P, Wang HQ, Zheng JS. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med. 2009 Dec 17;361(25):2414-23. doi: 10.1056/NEJMoa0908535. Epub 2009 Oct 21.</citation>
    <PMID>19846844</PMID>
  </reference>
  <reference>
    <citation>Mazza JJ, Yale SH, Arrowood JR, Reynolds CE, Glurich I, Chyou PH, Linneman JG, Reed KD. Efficacy of the influenza vaccine in patients with malignant lymphoma. Clin Med Res. 2005 Nov;3(4):214-20.</citation>
    <PMID>16303886</PMID>
  </reference>
  <reference>
    <citation>Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. Br J Haematol. 2005 Jul;130(1):96-8.</citation>
    <PMID>15982350</PMID>
  </reference>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2009</study_first_submitted>
  <study_first_submitted_qc>November 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2009</study_first_posted>
  <last_update_submitted>June 3, 2010</last_update_submitted>
  <last_update_submitted_qc>June 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>John Kuruvilla, MD</name_title>
    <organization>Princess Margaret Hospital</organization>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Multiple myeloma</keyword>
  <keyword>Leukemia, Lymphocytic, Chronic, B-Cell</keyword>
  <keyword>Influenza A Virus, H1N1 Subtype</keyword>
  <keyword>Influenza Vaccines</keyword>
  <keyword>Bone Marrow Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

